Despite recent advances in the detection and treatment of most cancers, cancer related mortality has not decreased in the United States. In the near future, cancer is predicted to overtake heart disease as the number one cause of death. It is clear that new approaches are needed to treat these diseases. Cancer is the result of disruption of the pathways that regulate cell proliferation. These pathways include mitogenic signals, growth inhibitory signals, and cell survival signals. Preliminary evidence suggests that these latter signals differ between normal cells and cancer cells, as well as between cancers derived from solid tissue cells and hematopoietic cells. We postulate that better understanding these differences will allow the development of novel cancer therapies. The overall goals of this proposal are to understand the perturbations in the programmed cell death (PCD) pathway in cancer cells, and to determine whether the differences between cancer cells and normal cells can be exploited to develop new therapeutic agents. To accomplish these goals, adenovirus vectors will be used to specifically inactivate inhibitory components of the PCD pathway. Viruses that target three different points in the PCD pathway will be analyzed. These vectors, the bcl-x, adenovirus, the mbm-2 adenovirus, and the hrk adenovirus have several qualities that make them ideal agents that can be used to study both the biology and biochemistry of the PCD pathway and used as gene therapy agents. Cancers of Breast, Ovarian, Bladder and Hematopoietic origin will be analyzed. These cancers were chosen to explore differences in PCD pathways in these tumors, and because adenovirus vectors have therapeutic potential in these diseases. The projects in this proposal are integrated to achieve these goals. Project #1, Biochemistry and function of hrk, will examine the role of a new gene, hrk, in PCD in normal and cancer cells. An adenovirus vector that expresses hrk will be made and used by each project to determine the role of this gene in PCD in each respective type of cancer cell. Project #2, Targeting PCD in Breast and Ovarian cancer cells will utilize each of the adenovirus vectors for effects on normal and malignant breast cancer cells. Animal models to test the utility of these vectors are described. Clinical trials using the bcl-x/s adenovirus in high dose chemotherapy and autologous BMT in breast cancer and for treatment of ascites in patients with ovarian cancer are planned. Project #3, targeting PCD in Leukemia, will explore the regulation of PCD in normal and leukemic hematopoietic cells. Strategies to use adenovirus to specifically kill leukemia cells contaminating the bone marrow of cells used for autologous BMT will be tested. Project #4, Targeting PCD in bladder cancer, will determine the role of the bcl-2 family in bladder cancer. Clinical trials using the bcl-x/s adenovirus are envisioned.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA075136-06
Application #
6628265
Study Section
Subcommittee G - Education (NCI)
Program Officer
Xie, Heng
Project Start
1998-04-01
Project End
2005-01-31
Budget Start
2003-04-11
Budget End
2005-01-31
Support Year
6
Fiscal Year
2003
Total Cost
$361,000
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Bockhorn, Jessica; Dalton, Rachel; Nwachukwu, Chika et al. (2013) MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 4:1393
Dontu, Gabriela; Abdallah, Wissam M; Foley, Jessica M et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253-70
Al-Hajj, Muhammad; Wicha, Max S; Benito-Hernandez, Adalberto et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-8
Hernandez-Alcoceba, Ruben; Pihalja, Michael; Qian, Dalong et al. (2002) New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 13:1737-50
Taj, M M; Tawil, R J; Engstrom, L D et al. (2001) Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. Prostate 47:194-204
Kielb, S J; Shah, N L; Rubin, M A et al. (2001) Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol 166:482-7
Hernandez-Alcoceba, R; Pihalja, M; Nunez, G et al. (2001) Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther 8:298-307
Sanz, C; Benito, A; Inohara, N et al. (2000) Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells. Blood 95:2742-7
Hernandez-Alcoceba, R; Pihalja, M; Wicha, M S et al. (2000) A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther 11:2009-24
Sumantran, V N; Lee, D S; Woods Ignatoski, K M et al. (2000) A bcl-xS adenovirus selectively induces apoptosis in transformed cells compared to normal mammary cells. Neoplasia 2:251-60

Showing the most recent 10 out of 13 publications